This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Johnson & Johnson, Oracle, SAP, Cigna and Walgreens Boots Alliance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Oracle, SAP, Cigna and Walgreens Boots Alliance
Top Research Reports for Johnson & Johnson, Oracle & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Oracle (ORCL), and SAP SE (SAP).
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
JNJ Beats on Q2 Earnings, Ups View: ETFs to Buy
by Sweta Killa
The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.
Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.
US States Get $26B Settlement Deal in Opioid Abuse Litigation
by Indrajit Bandyopadhyay
Attorney generals of several states reach settlement deal with J&J (JNJ) and three drug distributors - MCK, CAH and ABC - related to thousands of opioid abuse litigations. Non-participating states may join the deal soon.
Stock Market News for Jul 22, 2021
by Zacks Equity Research
U.S. stocks closed higher for the second successive day on Wednesday, as a string of upbeat earnings coupled with renewed optimism about the nation's economic recovery gave a boost to investors' confidence.
Coke, J&J, Verizon All Beat on Q2 Numbers
by Mark Vickery
Today's pre-market trading activity appears to have reverted back to the sector rotation between growth/tech names and cyclical/value stocks.
AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS
by Zacks Equity Research
The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
J&J (JNJ) Beats on Q2 Earnings & Sales, Ups View, Stock Rises
by Zacks Equity Research
J&J (JNJ) beats second-quarter 2021 estimates for both earnings and sales. It raises its financial expectations for the year. It forecasts $2.5 billion in 2021 sales of COVID-19 vaccine.
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 8.77% and 4.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for J&J (JNJ)
by Zacks Equity Research
J&J (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
A Big Week for Earnings: Global Week Ahead
by John Blank
In the Global Week Ahead, earnings reports move away from the major banks, into more interesting cyclical industry niches.
Fears of a Covid Resurgence Weigh on Equity Prices
by David Borun
With 40% of Americans still unvaccinated, an outbreak of delta-variant infections threatens the economic recovery.
Delta Variant Rattles Monday Pre-Market
by Mark Vickery
We're following last week's lower trading with a big drop: the Dow -475 points, the S&P 500 -50 and the Nasdaq -125.
Markets Look to Open in the Red on Delta Variant Fears
by Zacks Equity Research
Markets Look to Open in the Red on Delta Variant Fears
Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market. Market recovery might have led to continued recovery in Medical Devices segment in the second quarter.
5 Best Inverse/Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was subdued last week. A slew of earnings results for the second quarter and a new report on consumer spending for June came in stronger than expected. But increasing cases of the delta variant of COVID-19 also weighed on risk-on sentiments.
Netflix, Johnson & Johnson, JPMorgan, Citigroup and Wells Fargo are part of Zacks Earnings Preview
by Zacks Equity Research
Netflix, Johnson & Johnson, JPMorgan, Citigroup and Wells Fargo are part of Zacks Earnings Preview
Q2 Earnings Reports Confirm Economic Boom Ahead
by Sheraz Mian
We are off to a great start in the Q2 earnings season, with 2021 Q2 earnings projected to climb 14.5% above the comparable pre-Covid 2019 period...
Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall
by Kinjel Shah
Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.
J&J (JNJ) Recalls Some Sunscreens Due to Benzene Presence
by Zacks Equity Research
J&J (JNJ) withdraws five aerosol sunscreen products from the market due to "low levels" of benzene found in some samples.